Akero Therapeutics logo

Akero TherapeuticsNASDAQ: AKRO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 June 2019

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.14 B
-33%vs. 3y high
81%vs. sector
-vs. 3y high
-vs. sector
-72%vs. 3y high
68%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 45 min ago
$30.64-$0.58(-1.87%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

AKRO Latest News

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
globenewswire.com15 November 2024 Sentiment: POSITIVE

-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan ® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELF TM score (serum fibrosis biomarker) –

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
globenewswire.com08 November 2024 Sentiment: POSITIVE

— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH —

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
globenewswire.com21 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The presentations will highlight findings from the 96-week Phase 2b HARMONY study evaluating the efficacy and safety of lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3), along with insights from an analysis using AI and digital-based pathology.

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
globenewswire.com09 September 2024 Sentiment: POSITIVE

Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported the first patient was dosed in the Phase 3 SYNCHRONY Outcomes trial.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
prnewswire.com23 August 2024 Sentiment: NEGATIVE

NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
prnewswire.com17 July 2024 Sentiment: NEGATIVE

NEW YORK , July 17, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection with recent corporate actions.

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
zacks.com16 July 2024 Sentiment: POSITIVE

Akero Therapeutics (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
businesswire.com25 June 2024 Sentiment: NEGATIVE

LOS ANGELES--(BUSINESS WIRE)--AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!
accesswire.com25 June 2024 Sentiment: NEGATIVE

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Akero securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period").

AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
prnewswire.com25 June 2024 Sentiment: NEGATIVE

LOS ANGELES , June 25, 2024 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

What type of business is Akero Therapeutics?

Akero Therapeutics Inc. is a company specializing in cardiometabolic non-alcoholic steatohepatitis (NASH). The company focuses on developing drugs aimed at restoring metabolic balance and improving the overall health of patients with NASH. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to target the processes underlying the pathogenesis of NASH, with the potential to restore healthy liver fat metabolism, reduce hepatocyte stress, alleviate inflammation, and eliminate fibrosis. Efruxifermin is being developed in a separate cohort studying the treatment of patients with compensated liver cirrhosis (F4).

What sector is Akero Therapeutics in?

Akero Therapeutics is in the Healthcare sector

What industry is Akero Therapeutics in?

Akero Therapeutics is in the Biotechnology industry

What country is Akero Therapeutics from?

Akero Therapeutics is headquartered in United States

When did Akero Therapeutics go public?

Akero Therapeutics initial public offering (IPO) was on 20 June 2019

What is Akero Therapeutics website?

https://akerotx.com

Is Akero Therapeutics in the S&P 500?

No, Akero Therapeutics is not included in the S&P 500 index

Is Akero Therapeutics in the NASDAQ 100?

No, Akero Therapeutics is not included in the NASDAQ 100 index

Is Akero Therapeutics in the Dow Jones?

No, Akero Therapeutics is not included in the Dow Jones index

When was Akero Therapeutics the previous earnings report?

No data

When does Akero Therapeutics earnings report?

The next expected earnings date for Akero Therapeutics is 28 February 2025